--- canonical_name: Piceatannol alternate_names: 3,3',4,5'-tetrahydroxystilbene, trans-piceatannol, astringinin, PIC canonical_topic: Piceatannol for Health & Longevity short_topic_lc: piceatannol creation_date: 2026-0626-0156 creator_ai_fullname: Opus 4.8 --- # Piceatannol for Health & Longevity

Evidence Review created on 06/26/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** 3,3',4,5'-tetrahydroxystilbene, trans-piceatannol, astringinin, PIC ## Motivation Piceatannol is a naturally occurring plant compound in the same chemical family as resveratrol, the much-studied molecule from red wine and grape skins. It is found in modest amounts in grapes, blueberries, and white tea, and in concentrated form in the seeds of passion fruit. Chemically it carries one extra hydroxyl group than resveratrol, making it a stronger antioxidant in the test tube and, in animals, a body-produced byproduct of resveratrol itself. It is sold as a stand-alone supplement, often as a passion-fruit-seed extract. Interest in piceatannol grows out of the broader search for plant compounds that might switch on the body's own longevity and repair machinery, much as fasting and exercise do. Laboratory work suggests it can dampen inflammation, calm overactive immune signaling, and nudge metabolism toward fat burning. Early human findings on insulin response and blood pressure in a metabolically vulnerable group fueled commercial enthusiasm. This review examines what the evidence shows about piceatannol's possible benefits, its risks, how it is dosed, and how it interacts with everyday habits — separating the handful of human findings from the much larger body of cell and animal work. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level overviews and expert discussions that introduce piceatannol's chemistry, mechanisms, and therapeutic potential for a non-specialist reader. * [Biotransformation of Piceatannol, a Dietary Resveratrol Derivative: Promises to Human Health](https://pubmed.ncbi.nlm.nih.gov/31837280/) - Dai et al., 2020 This primary research paper traces how the body actually handles piceatannol, showing it is rapidly converted to two active metabolites and clears quickly, which frames the central challenge of using it as a supplement. * [Exploring the therapeutic potential of naturally occurring piceatannol in non-communicable diseases](https://pubmed.ncbi.nlm.nih.gov/37702264/) - Gandhi et al., 2024 A broad narrative review covering piceatannol's chemistry, food sources, mechanisms, and its anti-inflammatory, antioxidant, antidiabetic, and neuroprotective effects, with a frank discussion of its low bioavailability. * [A review of the pharmacological effects of piceatannol on cardiovascular diseases](https://pubmed.ncbi.nlm.nih.gov/24919577/) - Tang & Chan, 2014 A focused narrative review of the cardiovascular evidence, useful for understanding the vasorelaxant, cholesterol-lowering, and antioxidant actions proposed for the compound. * [Benefits of skin application of piceatannol — a minireview](https://pubmed.ncbi.nlm.nih.gov/36264002/) - Krambeck et al., 2023 A concise overview of the topical and skin-aging research, explaining why passion-fruit-seed piceatannol has attracted attention as a cosmetic and dermatological ingredient. * [Piceatannol: a natural stilbene for the prevention and treatment of cancer](https://pubmed.ncbi.nlm.nih.gov/31926274/) - Banik et al., 2020 A detailed narrative review of the preclinical anticancer work across many tumor types, valuable as a map of the mechanistic claims that remain untested in humans. ## Grokipedia [Piceatannol](https://grokipedia.com/page/piceatannol) The Grokipedia article provides a structured overview of piceatannol's chemistry, natural sources, molecular targets, and reported biological activities, serving as a quick orientation to the compound. ## Examine [Piceatannol](https://examine.com/supplements/piceatannol/) Examine's page summarizes piceatannol as a stilbene similar to resveratrol, noting that the two share many properties but that there is not yet enough evidence to conclude piceatannol is superior. ## ConsumerLab No dedicated ConsumerLab article or product test for piceatannol was found. ## Systematic Reviews No systematic reviews or meta-analyses for piceatannol were found on PubMed as of June 26, 2026. ## Mechanism of Action Piceatannol is a stilbene — a small two-ring plant molecule — that differs from resveratrol by one additional hydroxyl (oxygen-hydrogen) group on its ring. This extra group makes it a more powerful direct antioxidant, meaning it neutralizes reactive oxygen species (unstable, cell-damaging molecules) more efficiently than resveratrol in laboratory tests. Several overlapping pathways are proposed: * **Antioxidant and Nrf2 signaling.** Beyond directly scavenging free radicals, piceatannol activates Nrf2 (a master switch that turns on the cell's own protective antioxidant genes), increasing enzymes such as glutathione-related defenses. * **Anti-inflammatory action via NF-κB.** Piceatannol inhibits NF-κB (nuclear factor kappa B, a central controller of inflammatory gene activity), reducing production of inflammatory messengers. It also inhibits COX-2 (cyclooxygenase-2, an enzyme that makes pro-inflammatory prostaglandins). * **Syk kinase inhibition.** Piceatannol is a well-characterized inhibitor of Syk (spleen tyrosine kinase, an enzyme that relays activating signals inside immune cells), which underlies much of its anti-allergic and immune-modulating activity in the laboratory. * **Sirtuin and AMPK pathways.** Like resveratrol, piceatannol is reported to raise activity of SIRT1 (a longevity-associated enzyme that helps regulate metabolism and stress resistance) and AMPK (AMP-activated protein kinase, a cellular energy sensor that promotes fat burning). A human study found piceatannol intake raised SIRT1 messenger-RNA in whole blood. Competing mechanistic views exist. Skeptics argue that the antioxidant and sirtuin-activating effects seen at high test-tube concentrations may not occur at the very low blood levels reached after oral dosing, and that the body rapidly methylates piceatannol into other compounds, so observed effects may belong to its metabolites rather than piceatannol itself. **Key pharmacological properties:** Piceatannol has poor oral bioavailability and a short half-life. After absorption it undergoes extensive phase II metabolism — glucuronidation, sulfation, and O-methylation by COMT (catechol-O-methyltransferase, an enzyme that adds methyl groups to catechol compounds) — yielding active metabolites rhapontigenin and isorhapontigenin. It is broadly distributed but rapidly cleared. It is itself a substrate-inhibitor of COMT. ## Historical Context & Evolution * **Botanical and dietary origins.** Piceatannol was first characterized as a plant stilbene — a phytoalexin that plants produce to defend against fungal infection — and identified in grapes, the seeds of passion fruit, rhubarb, and white tea. Its original "use," in the plant, is purely defensive. * **The resveratrol connection.** Interest in piceatannol rose alongside the resveratrol boom of the early 2000s, when stilbenes were proposed as molecules that might mimic the longevity benefits of calorie restriction. Piceatannol gained attention as both a more potent antioxidant relative and a natural metabolite of resveratrol formed in the body by the enzyme CYP1B1. * **From mechanism to product.** Early findings that piceatannol inhibits Syk kinase made it a research tool in immunology before it was considered a supplement. Japanese work on passion-fruit-seed extracts in the 2010s — including a small human metabolic trial — drove its commercial development as an ingestible supplement and skin-care ingredient. * **Evolving understanding.** Initial enthusiasm rested almost entirely on cell and animal data. As pharmacokinetic studies clarified piceatannol's poor bioavailability and rapid conversion to metabolites, the field's framing shifted: rather than assuming test-tube potency translates to the body, more recent reviews emphasize that the active species in vivo may be its metabolites, and that human evidence remains thin. What changed was not a single "debunking" but a growing recognition that the gap between laboratory promise and human proof is wide and not yet closed. ## Expected Benefits A dedicated search across PubMed, web sources, and dedicated supplement databases was performed to assemble the complete benefit profile. The defining feature of the piceatannol literature is that nearly all benefits rest on cell and animal data; the small number of human trials are short, mostly industry-funded, and limited to specific subgroups. ### High 🟩 🟩 🟩 (No benefits qualify for the High evidence level. No large or replicated human randomized trials support any benefit of oral piceatannol.) ### Medium 🟩 🟩 (No benefits qualify for the Medium evidence level.) ### Low 🟩 #### Improved Insulin Sensitivity in Overweight Men In a randomized, placebo-controlled crossover trial in 39 Japanese adults, eight weeks of piceatannol (20 mg/day) lowered fasting insulin, insulin resistance (HOMA-IR, a calculated index of how resistant the body is to insulin), blood pressure, and heart rate — but only in the overweight men subgroup. Non-overweight men and all women showed no benefit. The effect is biologically plausible given piceatannol's reported actions on AMPK and adipose tissue, but the trial was small, single-center, manufacturer-involved, and positive only in a post-hoc subgroup, which keeps the evidence at the Low level. **Magnitude:** Not quantified in available studies. #### Increased SIRT1 Expression A randomized, double-blind, placebo-controlled trial in adults across a range of ages and body-mass indices (100 mg/day for two weeks) reported that oral piceatannol raised SIRT1 messenger-RNA in human whole blood versus placebo, paralleling in-vitro findings in skeletal-muscle cells. SIRT1 activation is the proposed link to longevity-related metabolic regulation. However, a change in gene-expression is a surrogate marker, not a clinical outcome, and the trial was industry-conducted. **Magnitude:** Not quantified in available studies. #### Skin Hydration and Wrinkle Reduction A randomized, double-blind, placebo-controlled trial of an oral piceatannol passion-fruit-seed drink in women reported improved facial skin hydration and reduced wrinkle severity, consistent with cell studies showing collagen stimulation and protection against ultraviolet damage. Independent commentary noted the trial ran from winter into spring, when rising ambient humidity can itself improve skin hydration, and that it was funded and staffed by the supplement manufacturer. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Anti-Inflammatory and Immune-Modulating Effects Through inhibition of NF-κB, COX-2, and Syk kinase, piceatannol reduces inflammatory and allergic signaling in cell and rodent models, raising the possibility of benefit in inflammation-driven conditions. No controlled human trials confirm a clinical anti-inflammatory effect; the basis is mechanistic and preclinical only. #### Cardiovascular Protection Animal and cell studies report vasorelaxation, antioxidant protection of blood vessels, reduced cholesterol, and anti-atherosclerotic actions, partly via inhibition of PCSK9 (a protein that lowers the liver's ability to clear LDL cholesterol). Human cardiovascular outcome data are absent; a 7-day human pilot found no improvement in endothelial (blood-vessel lining) function at rest or after exercise. #### Anticancer and Chemopreventive Activity Extensive preclinical work shows piceatannol can slow growth and trigger death of cancer cells across many tumor types in the laboratory. This is entirely cell-based and animal-based; no human evidence exists, and these findings do not translate into a benefit claim for healthy people. #### Neuroprotection In cell and rodent models, piceatannol protects neurons from oxidative and excitotoxic damage and engages SIRT3/FOXO3a and mitochondrial pathways. Its inhibition of COMT has been proposed as relevant to neurodegeneration. No human neurological data exist. #### Anti-Obesity / Fat Metabolism In mice, piceatannol modulates fat-cell proteins and gut bacteria and reduces fat accumulation; in adipose tissue it inhibits fat synthesis. Human weight or body-composition data are absent — the one human metabolic trial found no change in body weight or body composition. ## Benefit-Modifying Factors * **COMT activity (genetic):** Because COMT rapidly methylates piceatannol into metabolites, individual differences in COMT activity (including common COMT gene variants, where COMT is the enzyme that adds methyl groups to catechol compounds) may influence how much intact piceatannol versus metabolite a person is exposed to, and thus the response. * **Baseline metabolic status:** The clearest human benefit appeared only in overweight men with presumably higher baseline insulin resistance. People with normal insulin sensitivity may have little room to improve and showed no benefit in the trial. * **Sex differences:** In the metabolic trial, only men benefited. Sex and hormonal status appear to modify outcomes, though the data are too sparse to be firm. * **Pre-existing health conditions:** Benefits, where seen, cluster in those with metabolic dysfunction (overweight, insulin resistance). Healthy-weight individuals are the group least likely to see measurable effects based on current evidence. * **Age and metabolic status:** The SIRT1 trial enrolled adults across a range of ages and body-mass indices, so age- and metabolism-related differences may shape any longevity-relevant signaling effect, including at the older end of the target range, though the trial was not powered to confirm subgroup-specific responses. ## Potential Risks & Side Effects A dedicated search of drug-reference and supplement-safety sources was performed for the side-effect profile. Piceatannol is not a regulated drug and has no formal prescribing information; human safety data come almost entirely from a few short trials, where it was generally well tolerated, so most risks are inferred from mechanism. ### High 🟥 🟥 🟥 (No risks qualify for the High evidence level; no serious adverse effects have been established in humans.) ### Medium 🟥 🟥 (No risks qualify for the Medium evidence level.) ### Low 🟥 #### Generally Mild Tolerability with Limited Safety Data Across the small human trials (8 weeks at 20 mg/day and shorter studies), oral piceatannol was reported as well tolerated without notable adverse events. The principal risk is therefore the absence of long-term and high-dose safety data rather than a documented harm: no studies exceed a few months, none use large doses, and post-marketing surveillance does not exist for this supplement. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Bleeding / Antiplatelet Risk Stilbenes, and piceatannol's reported inhibition of platelet-activating signaling (including Syk-dependent pathways), raise a theoretical risk of reduced clotting, which could compound the effect of blood thinners. This is mechanistic and not demonstrated clinically in humans. #### Estrogenic / Hormonal Activity As a polyphenol structurally related to resveratrol, piceatannol may have weak interactions with estrogen signaling and steroid-hormone production, as suggested by reviews of grape polyphenols and steroidogenesis. The clinical relevance, including in hormone-sensitive conditions, is unknown. #### Drug-Metabolism Interactions By inhibiting COMT and acting on drug-metabolizing and transport pathways common to polyphenols, piceatannol could in theory alter levels of co-administered medications. No human interaction studies confirm this. #### Pregnancy and Lactation Uncertainty No safety data exist for piceatannol supplementation during pregnancy or breastfeeding, and its possible hormonal and signaling activities make use during these periods of unknown risk. ## Risk-Modifying Factors * **COMT genotype (genetic):** Variation in COMT activity could alter the balance of piceatannol and its methylated metabolites and, in theory, the degree of any COMT-inhibition-related effects, where COMT is the enzyme that methylates catechol compounds and several neurotransmitters. * **Baseline coagulation status:** People with low platelet counts or existing clotting abnormalities would be most exposed to any theoretical antiplatelet effect. * **Sex and hormonal status:** Given piceatannol's possible weak hormonal activity, individuals with hormone-sensitive conditions (and women versus men) may differ in susceptibility to hormonal effects; data are absent. * **Pre-existing health conditions:** Those on multiple medications, with bleeding disorders, or with hormone-sensitive cancers represent the populations where speculative risks would matter most. * **Age:** Older adults, more likely to be on anticoagulants and polypharmacy, would face greater theoretical interaction and bleeding risk, including at the older end of the target range. ## Key Interactions & Contraindications * **Anticoagulant and antiplatelet drugs:** Theoretical additive bleeding risk with warfarin, direct oral anticoagulants (apixaban, rivaroxaban), and antiplatelet agents (aspirin, clopidogrel). Severity: caution. Consequence: possible increased bleeding. Mitigation: avoid combining without medical supervision; monitor for bruising or bleeding. * **Over-the-counter NSAIDs:** Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen) and high-dose aspirin already affect platelets and the stomach lining; concurrent piceatannol could theoretically add to antiplatelet effect. Severity: caution. Consequence: potential additive bleeding tendency. * **Supplement interactions:** Other supplements with blood-thinning or antiplatelet effects — fish oil (EPA & DHA), high-dose vitamin E, ginkgo (*Ginkgo biloba*), garlic extract, and curcumin (*Curcuma longa*) — may have additive effects. Severity: caution. Mitigation: avoid stacking multiple antiplatelet supplements. * **Additive antioxidant/sirtuin supplements:** Resveratrol, pterostilbene, and quercetin share overlapping pathways and metabolism; combining may increase competition for COMT-mediated methylation and alter exposure. Severity: monitor. * **COMT-dependent drugs and substrates:** Because piceatannol inhibits COMT, it could theoretically affect drugs metabolized by or interacting with this enzyme (e.g., COMT inhibitors such as entacapone, or catecholamine-based medications). Severity: caution. Mitigation: separate dosing and seek medical advice. * **Populations who should avoid this intervention:** Pregnant or breastfeeding individuals (no safety data); people with bleeding disorders or scheduled surgery within roughly 2 weeks (discontinue before procedures); those on anticoagulants without supervision; and individuals with hormone-sensitive cancers, given unresolved hormonal-activity questions. ## Risk Mitigation Strategies * **Conservative dosing:** Stay at or near the only human-tested oral dose (20 mg/day) rather than extrapolating to high doses from animal studies, mitigating the risk posed by the absence of high-dose safety data. * **Perioperative discontinuation:** Stop piceatannol approximately 1–2 weeks before any planned surgery or dental procedure, mitigating the theoretical antiplatelet/bleeding risk. * **Avoid antiplatelet stacking:** Do not combine with anticoagulants, antiplatelet drugs, or multiple blood-thinning supplements (fish oil, ginkgo, high-dose vitamin E) without medical oversight, mitigating additive bleeding risk. * **Screen for hormone-sensitive conditions:** Given unresolved questions about weak hormonal activity, those with hormone-sensitive cancers or pregnancy/lactation should avoid use, mitigating the speculative estrogenic risk. * **Time-limited trials with reassessment:** Because long-term safety is uncharacterized, use defined periods (e.g., 8–12 weeks) with reassessment rather than indefinite open-ended use, mitigating the risk of unknown chronic effects. ## Therapeutic Protocol * **Standard dose:** The only oral dose tested in a human metabolic trial is 20 mg/day of piceatannol (delivered as a passion-fruit-seed extract), taken for 8 weeks. Skin and SIRT1 trials used comparable passion-fruit-seed extract preparations. There is no established "leading practitioner" protocol because clinical use is minimal. * **Competing approaches:** The main alternative framing is to use resveratrol or pterostilbene instead, since these are far better studied; some practitioners view piceatannol as a more potent but less-proven option, and others favor obtaining stilbenes from whole foods (grapes, berries, passion fruit) rather than isolated supplements. No approach is established as the default. * **Popularizing source:** Commercial passion-fruit-seed piceatannol (e.g., the Passienol-type extracts) was developed and studied largely by Japanese researchers and the manufacturer Morinaga, which conducted the key human trials. * **Best time of day:** Not formally established. Given the metabolic and insulin-related findings, taking it with a meal is reasonable to align with post-meal metabolic handling, though no timing study exists. * **Half-life:** Piceatannol has a short half-life and is rapidly cleared after extensive phase II metabolism; intact piceatannol exposure is brief. * **Single vs. split dosing:** Because of rapid clearance, split dosing might in theory sustain exposure, but human trials used once-daily dosing, so once-daily is the only evidence-based pattern. * **Genetic factors:** COMT variants may influence the ratio of piceatannol to its methylated metabolites and thus response; no pharmacogenetic dosing guidance exists. * **Sex differences:** The metabolic trial suggests men may respond metabolically; sex-specific dosing signals are otherwise too preliminary to drive dosing. * **Age considerations:** No age-specific dosing exists; older adults on other medications should be more cautious about interactions, including at the older end of the target range. * **Baseline biomarkers:** Those with elevated fasting insulin or insulin resistance are the subgroup most likely to show the documented metabolic benefit. * **Pre-existing conditions:** Overweight/insulin-resistant individuals showed the clearest benefit; people with bleeding disorders or hormone-sensitive conditions should avoid use. ## Discontinuation & Cycling * **Lifelong vs. short-term:** There is no evidence supporting indefinite use; human trials ran only 8 weeks or less, so any use is best regarded as a time-limited experiment rather than a lifelong regimen. * **Withdrawal effects:** No withdrawal effects have been reported or are mechanistically expected, given the compound's rapid clearance. * **Tapering:** No tapering is needed; piceatannol can be stopped abruptly without known consequence. * **Cycling:** No cycling protocol has been studied or established. Whether intermittent use preserves any sirtuin- or metabolism-related effects is unknown. ## Sourcing and Quality * **Source form:** Most commercial piceatannol is supplied as a passion-fruit (*Passiflora edulis*) seed extract standardized to a stated piceatannol content; synthetic and grape-derived material also exists. Look for products that specify the actual piceatannol dose, not just total extract weight. * **Third-party testing:** Because supplements are not pre-approved for purity, prefer products with third-party certification (e.g., NSF, USP, or independent certificate-of-analysis verifying piceatannol content and screening for contaminants). * **Standardization:** Confirm the label states a quantified piceatannol amount (e.g., 20 mg) and the extract ratio, since passion-fruit-seed piceatannol content varies considerably by source. * **Reputable suppliers:** Branded passion-fruit-seed ingredients used in published trials (such as the Morinaga Passienol-type extract) provide more traceable provenance than generic bulk powders; reputable supplement brands that publish certificates of analysis are preferable. * **Stability:** As a polyphenol, piceatannol is susceptible to oxidation; products in opaque, sealed packaging stored away from heat and light are preferable. ## Practical Considerations * **Time to effect:** Metabolic changes in the human trial were measured after 8 weeks; skin outcomes also accrued over weeks. No rapid, perceptible effect should be expected, and any benefit is likely modest and gradual. * **Common pitfalls:** Assuming that potent test-tube antioxidant activity translates to the body — it largely does not, because of poor bioavailability; over-dosing based on animal studies; expecting benefit despite normal metabolic health (the trial showed benefit only in overweight men); and conflating piceatannol with the far better-studied resveratrol. * **Regulatory status:** In the United States piceatannol is sold as a dietary supplement, not an approved drug; it is not FDA-evaluated for treating any condition. There is no recognized medical (off-label) use. * **Cost and accessibility:** Piceatannol supplements are a niche product, generally more expensive and less widely available than resveratrol, though not prohibitively costly. ## Interaction with Foundational Habits * **Sleep:** Interaction direction: none established. There is no evidence that piceatannol disrupts or improves sleep; no stimulant or sedative activity has been reported, and no human study assessed sleep outcomes. * **Nutrition:** Interaction direction: potentiating (indirect). Piceatannol occurs naturally in passion fruit, grapes, berries, and white tea, so a polyphenol-rich diet contributes background intake; taking the supplement with a meal is reasonable to align with post-meal metabolic handling. No specific food needs to be avoided, and whole-food sources are a practical alternative. * **Exercise:** Interaction direction: uncertain. Mechanistically, piceatannol's reported AMPK and SIRT1 effects overlap with exercise-induced pathways, raising a theoretical question of whether high-dose antioxidant supplementation could blunt some exercise adaptations (as debated for other antioxidants). A 7-day human pilot found no improvement in endothelial function after exercise, and no study shows it enhances training; timing around workouts is unstudied. * **Stress management:** Interaction direction: none established. No human data link piceatannol to cortisol or the stress response, though its general anti-inflammatory and antioxidant actions are sometimes invoked speculatively; no practical stress-related protocol is supported. ## Monitoring Protocol & Defining Success Because the documented human benefit centers on metabolic markers in insulin-resistant individuals, baseline and follow-up testing focuses on glucose-insulin and cardiovascular measures. Baseline labs should be drawn before starting to establish a personal reference point. Ongoing monitoring is reasonable at baseline, then around 8–12 weeks to match the timeframe over which trial effects appeared, and thereafter every 6–12 months if use continues. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --------- | ------------------------ | --------------- | ------------- | | Fasting insulin | 2–5 µIU/mL | Most direct marker of the trial's primary benefit | Fasting required; pairs with fasting glucose for HOMA-IR (insulin-resistance index) | | Fasting glucose | 75–90 mg/dL | Tracks glucose control alongside insulin | Fasting required; conventional "normal" extends to 99 mg/dL but functional target is tighter | | HbA1c | < 5.4% | Longer-term (3-month) glucose average | No fasting needed; HbA1c is glycated hemoglobin, reflecting average blood sugar | | Blood pressure | < 120/80 mmHg | Trial showed reductions in overweight men | Measure seated, rested; multiple readings preferred | | Resting heart rate | 50–70 bpm | Reduced in the trial subgroup | Best measured at rest, same time of day | | hs-CRP | < 1.0 mg/L | Gauges any anti-inflammatory effect | hs-CRP is high-sensitivity C-reactive protein; avoid testing during acute illness | | Lipid panel (LDL, HDL, triglycerides) | LDL < 100 mg/dL; triglycerides < 100 mg/dL | Cardiovascular mechanism is proposed | Fasting preferred for triglycerides | * **Qualitative markers:** The following subjective markers can be tracked alongside labs: - Energy levels and exercise tolerance - Skin hydration and appearance (relevant given the dermatological trial) - Body composition and waist measurement - General well-being and any signs of easy bruising or bleeding (a safety check) ## Emerging Research * **Skin-aging RCT (2026):** A randomized, double-blind, placebo-controlled trial reported that oral piceatannol improved skin hydration and reduced wrinkle severity — [Seto et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42131241/). The finding is tempered by seasonal confounding and manufacturer sponsorship, and would need independent replication to strengthen the case. * **Endothelial-function pilot (2025):** A human pilot study found that 7 days of piceatannol did not improve blood-vessel (endothelial) function at rest or after exercise — [Kasai et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41508641/). This is an example of emerging human data that weakens, rather than strengthens, a proposed cardiovascular benefit. * **SIRT1 mechanism trial (2024):** A randomized trial linking oral piceatannol to increased SIRT1 expression in human blood — [Tanaka et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38792610/) — points toward longevity-relevant signaling, but uses a surrogate marker and needs clinical-outcome follow-up. * **Bioavailability and metabolite focus:** Pharmacokinetic work showing rapid conversion to rhapontigenin and isorhapontigenin — [Dai et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31837280/) — has reframed future research toward the metabolites and toward delivery systems (liposomes, cubosomes) designed to raise bioavailability, an area that could change current understanding if successful. * **Neuroprotection direction:** Reviews such as [Hossain et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41420771/) map mechanistic targets for neurological disorders, but this remains preclinical and would require human trials to become relevant to the target audience. * **Ongoing trials:** A direct ClinicalTrials.gov search for piceatannol as an intervention returned no dedicated, registered human trials of oral piceatannol for health or longevity endpoints as of the review date; the registry's piceatannol-tagged records concern unrelated products. No relevant NCT IDs are therefore available to list. ## Conclusion Piceatannol is a plant compound closely related to resveratrol, found mainly in passion fruit seeds and grapes, and sold as a niche supplement. In the test tube it is a strong antioxidant and engages pathways tied to inflammation, immune signaling, and the body's longevity-linked enzymes. The trouble is that very little of this has been confirmed in people. The human evidence is limited to a handful of short studies: a metabolic trial that improved insulin response, blood pressure, and heart rate only in overweight men; a study showing it can raise a longevity-related gene's activity in blood; and a skin study reporting better hydration and fewer wrinkles. A blood-vessel study found no benefit. Most of these trials were run or funded by the product's maker and measured indirect markers rather than real health outcomes. The broad claims around cancer, brain protection, and heart health rest entirely on cell and animal work. The compound also clears the body quickly and is rapidly converted into other molecules, so its real-world effects remain uncertain. It appears well tolerated in the short term, but long-term safety is unknown. For someone focused on long-term health, piceatannol is an early-stage, lightly evidenced option whose promise is mostly still on the laboratory bench. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**